Skip to content

Development of a standardised non-medical treatment for inducible laryngeal obstruction

Inducible Laryngeal Obstruction in adults: developing a standardised non-pharmacological Intervention

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN18291587
Enrollment
34
Registered
2024-01-25
Start date
2024-03-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inducible Laryngeal Obstruction in adults Ear, Nose and Throat

Interventions

Stage 1: A 60-90 minutes focus group (with 5-7 experienced health care professionals experienced in delivering non-pharmacological interventions to adults with ILO) Stage 2: One-to-one (30-45 minutes

Sponsors

University of Manchester
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthcare professionals: 1. Experienced (defined as holding a regular ILO caseload for >3 years) in assessing, diagnosing and delivering nonpharmacological treatment to adults with ILO Treatment naïve patients: 1. An established diagnosis of ILO based on i) clinical evaluation AND ii) endoscopic visualisation of laryngeal obstruction during a symptomatic episode 2. >18 years old 3. Have not received and completed non-pharmacological / behavioural therapy intervention for ILO Post-treatment patients: 1. An established diagnosis of ILO based on i) clinical evaluation and ii) endoscopic visualisation of laryngeal obstruction during a symptomatic episode 2. >18 years old 3. Have received and completed a non-pharmacological behavioural therapy intervention for ILO

Exclusion criteria

Exclusion criteria: Healthcare professionals: 1. Healthcare professionals who have no specialist experience in assessing, diagnosing and delivering nonpharmacological treatment to adults with ILO Treatment naïve patients: 1. Have received any previous therapy intervention for ILO, refractory chronic cough or upper airway symptoms (e.g. muscle tension dysphonia, globus pharyngeaous) 2. Have uncontrolled asthma airway inflammation or obstruction (defined as fractional exhaled nitric oxide >50ppb, FEV1/FVC 50ppb, FEV1/FVC <70%)

Design outcomes

Primary

MeasureTime frame
Participant opinions/responses (variable) to questions regarding non-pharmacological interventions for ILO will be measured in a focus group/interview at a single timepoint using data transcript thematic analysis

Secondary

MeasureTime frame
Participant responses (variable) to a debriefing questionnaire on a draft standardised treatment manual for ILO will be measured at a single timepoint using thematic analysis

Countries

England, United Kingdom

Contacts

Public ContactJemma Haines
jemma.haines@mft.nhs.uk+44 (0)161 2914245

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 7, 2026